Back to Cell Types

C-33 AHomo sapiens (Human)Cancer cell line

Also known as: C33, C-33A, C-33-A, C33-A, C33a, C33A

🤖 AI SummaryBased on 12 publications

Quick Overview

C-33 A is a human cervical cancer cell line with HPV-negative status, used in cancer research.

Detailed Summary

C-33 A is a human cervical cancer cell line that is HPV-negative, making it a valuable model for studying cervical cancer without the influence of human papillomavirus (HPV). This cell line has been extensively studied for its genetic and molecular characteristics, particularly in relation to tumor suppressor genes such as p53 and RB. Research has shown that C-33 A exhibits mutations in the RB gene, leading to the production of abnormal pRB proteins. Additionally, studies have identified disruptions in the Smad4 gene, which is associated with TGF-β signaling pathways. These characteristics make C-33 A a critical tool for understanding the molecular mechanisms underlying cervical carcinogenesis and for evaluating therapeutic strategies targeting these pathways.

Research Applications

Study of HPV-negative cervical cancerInvestigation of p53 and RB gene mutationsAnalysis of Smad4 gene disruptionsEvaluation of TGF-β signaling pathways

Key Characteristics

HPV-negative statusMutations in RB geneDisruption of Smad4 geneAbnormal pRB protein expression

Generated on 6/16/2025

Basic Information

Database ID	CVCL_1094
Species	Homo sapiens (Human)
Tissue Source	Uterus, cervix[UBERON:UBERON_0000002]

Donor Information

Age	66
Age Category	Adult
Sex	Female

Disease Information

Disease	Squamous cell carcinoma of the cervix uteri
Lineage	Cervix
Subtype	Cervical Squamous Cell Carcinoma
OncoTree Code	CESC

DepMap Information

Source Type	ATCC
Source ID	ACH-001333_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Arg273Cys (c.817C>T)	Homozygous	-	PubMed=35933914

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X

CSF1PO

12

D13S317

13

D16S539

13,14

D18S51

15,17,18

D19S433

11,13,14

D21S11

29,30,31

D2S1338

23,25

D3S1358

16

D5S818

11,12

D7S820

10

D8S1179

10,14

FGA

21,25,26

Penta D

10

Penta E

6,8

TH01

7,8

TPOX

9

vWA

18,20

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Establishment, authenticity, and characterization of cervical cancer cell lines.

Garcia-Carranca A.M., Cerbon-Cervantes M.A., Alcantara-Quintana L.E.

Mol. Cell. Oncol. 9:2078628.1-2078628.10(2022).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines.

Frederick M.J., Myers J.N., Pickering C.R., Johnson F.M.

Oncotarget 8:86369-86383(2017).

Cervical cancer cell line secretome highlights the roles of transforming growth factor-beta-induced protein ig-h3, peroxiredoxin-2, and NRF2 on cervical carcinogenesis.

Loutradis D., Vlahou A., Anagnou N.P., Pappa K.I.

BioMed Res. Int. 2017:4180703.1-4180703.15(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Individual karyotypes at the origins of cervical carcinomas.";

Duesberg P.H.

Mol. Cytogenet. 6:44.1-44.23(2013).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Smad4 deficiency in cervical carcinoma cells.";

Schwarte-Waldhoff I.

Oncogene 24:810-819(2005).

Long-term cultivation of hypodiploid human tumor cells.";

Auersperg N.

J. Natl. Cancer Inst. 32:135-163(1964).

Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.

Rousset M., Zweibaum A., Fogh J.

Cancer Res. 41:1165-1170(1981).

Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.

Wright W.C., Daniels W.P., Fogh J.

J. Natl. Cancer Inst. 66:239-247(1981).

Human tumor lines for cancer research.";

Fogh J.

Cancer Invest. 4:157-184(1986).

Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines.

Yee C., Krishnan-Hewlett I., Baker C.C., Schlegel R., Howley P.M.

Am. J. Pathol. 119:361-366(1985).

The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines.

Scheffner M., Munger K., Byrne J.C., Howley P.M.

Proc. Natl. Acad. Sci. U.S.A. 88:5523-5527(1991).

Absence of HeLa cell contamination in 169 cell lines derived from human tumors.

Fogh J., Wright W.C., Loveless J.D.

J. Natl. Cancer Inst. 58:209-214(1977).

One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.

Fogh J., Fogh J.M., Orfeo T.

J. Natl. Cancer Inst. 59:221-226(1977).

Web Resources

thermofisher.com